Tallett Elizabeth E 4

What Happened

• Elizabeth E. Tallett, a director at Moderna (MRNA), had 4,058 restricted stock units (RSUs) vest and convert into 4,058 common shares on April 30, 2026. The Form 4 reports the conversion/acquisition of 4,058 shares and a simultaneous disposition of 4,058 shares at $0.00.
• No cash proceeds are reported for the disposition (listed as $0.00), and the acquisition price for the conversion is shown as N/A — this was an award vesting/conversion rather than an open-market buy or sell.

Key Details

• Transaction date: April 30, 2026; Form 4 filed May 4, 2026 (filed within the standard two-business-day window).
• Shares acquired by conversion: 4,058 common shares (RSU conversion).
• Shares disposed: 4,058 at $0.00 (reported as a disposition of the converted shares).
• Footnotes: F1 — RSUs convert into common stock on a one-for-one basis. F2 — the RSU award vested in full on April 30, 2026.
• Shares owned after transaction: not specified in the provided filing details.

Context

• The filing represents RSU vesting/conversion (derivative conversion). A simultaneous disposition at $0.00 commonly indicates shares were surrendered or withheld to satisfy tax withholding obligations rather than a market sale; the filing does not show cash proceeds.
• This is routine insider reporting of compensation vesting rather than a purchase that signals fresh insider buying.